Assessment of the effect of platelet plasma on blood biochemical parameters in an experimental model of knee osteoarthritis

P.V. Tkachuk, S.S. Strafun, O.B. Kumchenko, S.I. Savosko, I.V. Gayevich, O.M. Makarenko, L.S. Mkhitaryan, T.F. Drobotko


Platelet-rich plasma (PRP) has been proposed for use in cellular therapy of the knee arthrosis. In this study, we aimed to determine the effect of PRP on the state of the prooxidant-antioxidant balance and the product of peroxidation of the blood in dystrophic changes associated with the knee arthrosis. PRP was obtained from donor fresh blood at a concentration of 0.8–1 • 106 per 1 ml and was injected into the knee joint one month after modeling of arthrosis in rabbits. After 2.5 months, the concentration of free radical oxidation products of proteins, TBK-active products, diene conjugates, ceruloplasmin and reduced glutathione was measured in rabbit serum. The activity of catalase, SOD, paraoxonase-1 and leukocyte elastase and myeloperoxidase was evaluated. Local administration of 0.5 ml of PRP into the joint cavity was found to reduce dystrophic changes in the cartilage of the articular surface, as determined by the histological examination. The results of the study demonstrated the reduced activity of leukocyte elastase myeloperoxidase, the concentration of peroxidation products (diene conjugates, TBA-active products, products of free radical oxidation of proteins), restoration of activity of antioxidant system enzymes (catalase, SOD) and ceruloplasmin. The decrease in the activity of the enzymes of peripheral blood leukocytes can be considered as one of the indicators of reduction of the inflammatory process in arthrosis, and the restoration of the prooxidant-antioxidant balance may prevent dystrophic changes of the cartilage under the influence of PRP.


platelet-rich plasma; arthrosis; knee joint; peroxide oxidation products; prooxidant-antioxidant balance


Дубровин Г.М., Лебедев А.Ю. Прогнозирование и профилактика развития посттравматического гонартроза при внутрисуставных переломах костей коленного сустава. Хирургия. Журнал им. Н.И. Пирогова. 2018. 12. 106-110.

Chaves H.V., Ribeiro R., de Souza A.M. et al. Experimental model of zymosan-induced arthritis in the rat temporomandibular joint: role of nitric oxide and neutrophils. J. Biomed. Biotechnol. 2011. 2011. 707985.

Troeberg L., Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochimica et biophysicaacta. 2011. 1824 (1). 133-145.

Muley M.M., Reid A.R., Botz B., Bölcskei K., Helyes Z., McDougall J.J. Neutrophil elastase induces inflammation and pain in mouse knee joints via activation of proteinase-activated receptor-2. BJP. 2015. 173 (4). 766-777.

Breedveld F.C. Osteoarthritis — the impact of a serious disease. Rheumatology (Oxford). 2004. 43 (Suppl. 1). i4-8.

DeLong J.M., Russell R.P., Mazzocca A.D. Platelet-rich plasma: the PAW classification system. Arthroscopy. 2012. 28 (7). 998-1009.

Shahid M., Kundra R. Platelet-rich plasma (PRP) for knee disorders. EFORT Open Rev. 2017. 2 (1). 28-34.

Sánchez M., Anitua E., Delgado D. et al. Platelet-rich plasma, a source of autologous growth factors and biomimetic scaffold for peripheral nerve regeneration. Expert Opin. Biol. Ther. 2017. 17 (2). 197-212.

Marx R.E. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant. Dent. 2001. 10 (4). 225-228.

Чернишенко В., Штайнберг К., Луговська Н. та ін. Приготування висококонцентрованої аутологічної плазми крові, збагаченої тромбоцитами, для біомедичного використання. Укр. біохім. журн. 2019. 91 (2). 19-27.

Dhurat R., Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review and author's perspective. JCAS. 2014. 7 (4). 189-97.

Wasterlain A.S., Braun H.J., Harris A.H., Kim H.J., Dragoo J.L. The systemic effects of platelet-rich plasma injection. Am. J. Sports Med. 2013. 41 (1). 186-193.

Anitua E., Andia I., Ardanza B., Nurden P., Nurden A.T. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb. Haemost. 2004. 91 (1). 4-15.

Abegão K.G., Bracale B.N., Delfim I.G. et al. Effects of heterologous platelet-rich plasma gel on standardized dermal wound healing in rabbits. Acta Cir. Bras. 2015. 30 (3). 209-215.

Barrionuevo D.V., Laposy C.B., Abegão K.G. et al. Comparison of experimentally-induced wounds in rabbits treated with different sources of platelet-rich plasma. Lab. Anim. 2015. 49 (3). 209-214.

Manolescu B.N., Berteanu M., Cinteza D. Effect of the nutritional supplement ALA nerv on the serum PON1 activity in postacute stroke patients. Pharmacol. Rep. 2013. 65 (3). 743-750.

Горудко И.В., Костевич В.А., Соколов А.В. и др. Повышенная активность миелопероксидазы — фактор риска ишемической болезни сердца у больных сахарным диабетом. Биомед. химия. 2012. 58 (4). 475-484.

Спосіб визначення активності макрофагальної еластази: пат. 28914 UA. МПК G 01 N 33/50 / Кубишкін А.В., Пальона Ю.В., Фомочкіна І.І. Опубл. 25.12.2007, Бюл. № 21.

Королюк M.А., Иванова M.И., Майорова И.Г., Токарев В.Е. Метод определения активности каталазы. Лаб. дело. 1988. 1. 16-19.

Стальная И.Д., Гаришвили Т.Г. Метод определения малонового диальдегида с помощью тиобарбитуровой кислоты. Современные методы в биохимии. Под ред. В.Н. Ореховича. М.: Медицина, 1977. 66-68.

Камышников В.С. Справочник по клинико-биохимической лабораторной диагностике: В 2 т. Т. 2. Мн.: Беларусь, 2000. 74-75.

Кузьминская У.А. Биохимические, иммунологические и биофизические методы в токсикологическом эксперименте. Методическое руководство. К.: Здоровье, 1989. 23-25.

Stoppiello L.A., Mapp P.I., Wilson D. et al. Structural associations of symptomatic knee osteoarthritis. Arthritis & rheumatology (Hoboken, N.J.). 2014. 66 (11). 3018-3027.

Glynn L.G., Mustafa A., Casey M. et al. Platelet-rich plasma (PRP) therapy for knee arthritis: a feasibility study in primary care. Pilot and feasibility studies. 2018. 4. 93.

Ubilla D., Ananías J., Ortiz-Muñoz L., Irarrázaval S. Is platelet-rich plasma effective for osteoarthritis? Medwave. 2018. 8 (3). e7215.

Muley M.M., Krustev E., Reid A.R., McDougall J.J. Prophylactic inhibition of neutrophil elastase prevents the development of chronic neuropathic pain in osteoarthritic mice. Journal of neuroinflammation. 2017. 14 (1). 168.

Platelet-rich plasma compositions: рat. US 9,233,126 B2. Sanchez J.A., Navarro C.F., Trullas J.C., Safont L.O., Corominas E.G. Publ. 12.01.2016.

Страфун С.С., Вовченко А.Я., Гайович І.В. Застосування факторів росту у хворих із застарілими пошкодженнями ротаторної манжети плеча. Травма. 2011. 12 (1). 65-68.

Steinbeck M.J., Nesti L.J., Sharkey P.F., Parvizi J. Myeloperoxidase and chlorinated peptides in osteoarthritis: potential biomarkers of the disease. J. Orthop. Res. 2007. 25 (9). 1128-1135.

De Vries M.A., Alipour A., Birnie E. et al. Coronary leukocyte activation in relation to progression of coronary artery disease. Front. Med. 2016. 10 (1). 85-90.

Stamp L.K., Khalilova I., Tarr J.M. et al. Myeloperoxidase and oxidative stress in rheumatoid arthritis. Rheumatology (Oxford). 2012. 51 (10). 1796-1803.

Chapman A.L., Mocatta T.J., Shiva S. et al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J. Biol. Chem. 2013. 288 (9). 6465-6477.

Segelmark M., Persson B., Hellmark T., Wieslander J. Binding and inhibition of myeloperoxidase (MPO): a majorfunction of ceruloplasmin? Clin. Exp. Immunol. 1997. 108. 167-174

Conforti A., Franco L., Menegale G. et al. Serum copper and ceruloplasmin levels in rheumatoid arthritis and degenerative joint disease and their pharmacological implications. Pharmacol. Res. Commun. 1983. 15 (9). 859-867.

Strecker D., Mierzecki A., Radomska K. Copper levels in patients with rheumatoid arthritis. Ann. Agric. Environ. Med. 2013. 20 (2). 312-316.

Scott J.L., Gabrielides C., Davidson R.K. et al. Superoxide dismutase downregulation in osteoarthritis progression and end-stage disease. Ann. Rheum. Dis. 2010. 69 (8). 1502-1510.

Tikhova Y., Dvorshchenko K., Dranitsina A. et al. Prooxidant — antioxidant status and Ptgs2, Nos2 genes expression in rat cartilage with osteoarthritis and after the treatment of chondroitin sulfate. RJPBCS. 2017. 8 (4). 994-1001.

Kajanachumpol S., Vanichapuntu M., Verasertniyom O., Totemchokchyakarn K., Vatanasuk M. Levels of plasma lipid peroxide products and antioxidant status in rheumatoid arthritis. Southeast. Asian J. Trop. Med. Public. Health. 2000. 31 (2). 335-338.

Copyright (c) 2019 TRAUMA

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта